Management of Dyslipidemia in Patients After Solid Organ Transplantation
Authors:
- Lisa R. TannockLTLisa R. Tannock
- L. Raymond ReynoldsLRL. Raymond Reynolds
- MdMDMd
- FacpFAFacp
- FaceFAFace
- 1 January 2008
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 120 (1) , 43-49
Abstract
The increase in organ transplantation has led to primary care physicians assuming a greater role in the provision of health care. Cardiovascular disease is the leading cause of mortality in transplant patients. The risk factors for cardiovascular disease do not differ from the nontransplant population, except that there is increased prevalence of these risk factors in the transplant population. Post-transplant hyperlipidemia is extremely prevalent, partly because of the underlying condition causing the need for transplantation and partly because of the side effects of immunosuppressant agents. Although there are no large, cardiovascular event outcome trials demonstrating a benefit for lipid-lowering therapy in the transplant population, there is robust literature supporting this treatment in the nontransplant population, and numerous smaller trials in transplant patients have demonstrated the safety and efficacy of lipid-lowering therapy. This article reviews the evidence and treatment options for currently available lipid-lowering therapy in solid-organ transplant patients.Keywords
This publication has 28 references indexed in Scilit:
- Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Heart Transplant Report—2007The Journal of Heart and Lung Transplantation, 2007
- Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart–Lung Transplantation Report—2007The Journal of Heart and Lung Transplantation, 2007
- Hyperlipidemia After Renal Transplantation and Its Relation to Graft and Patient SurvivalTransplantation Proceedings, 2007
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1Transplantation, 2003
- Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialThe Lancet, 2003
- Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient MiceAmerican Journal of Transplantation, 2003
- HYPERCHOLESTEROLEMIA IS ASSOCIATED WITH INCREASED KIDNEY GRAFT LOSS CAUSED BY CHRONIC REJECTION IN MALE PATIENTS WITH PREVIOUS ACUTE REJECTIONTransplantation, 2000
- CHOLESTEROL AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER RENAL TRANSPLANTATIONTransplantation, 2000
- Hyperlipidemia in liver transplant recipients: Prevalence and risk factorsLiver Transplantation and Surgery, 1997